Current technology to numerically expand hemopoietic stem/progenitor cells (HSPC) ex vivo within 1 to 2 weeks is insufficient to warrant significant gain in reconstitution time following their transplantation. In order to more stringently test the parameters affecting HSPC expansion, we followed ex vivo cultures of CD34 
Introduction
Ex vivo expansion of repopulating HSPC may aid in abrogation of neutropenia in cancer patients receiving myeloablative high-dose chemotherapy. It may also open new opportunities for stem cell transplantation in cases where limited HSPC are available, such as in UCB grafts and leukapheresis samples from heavily pretreated patients. In addition, expansion may contribute in developing culture conditions that permit efficient gene transfer into primitive HSPC without their concurrent differentiation-induced loss. Although expansion of total nucleated cells and progenitors has been documented, infusion of these cells has not resulted in any improvement of the time to recovery of neutrophils or platelets. Up to date, most research on ex vivo expansion has explored different combinations of cytokines or chemokines, culture medium ingredients, and recently the role of stromal support. [1] [2] [3] [4] [5] [6] [7] Flt3-ligand (FL), thrombopoietin (TPO), stem cell factor (SCF) and interleukin-6 (IL6) are known to be early acting cytokines and have been reported to support primitive HSPC proliferation with maintenance of long-term repopulating ability. [8] [9] [10] [11] The important effects of these cytokines on early HSPC have led to the development of in vitro culture systems in order to expand these cells. Particularly, the long-term production of HSPC has been used as a stringent endpoint for HSPC maintenance or expansion. [12] [13] [14] [15] [16] [17] [18] Using a cytokine-supplemented stroma-free extended long-term culture (ELTC) system Piacibello and colleagues 19, 20 have uniquely documented a dramatic expansion of primitive CD34
+ UCB cells over periods as long as 30 weeks. Endpoints of primitivity in these studies included CD34 +
CD38
− and long-term culture initiating cell (LTC-IC) subsets. Recently, these authors also demonstrated that the NOD/SCID repopulating cells were markedly expanded using FL, TPO, SCF and IL6 under the same conditions after 10 weeks of culture. 21 Additionally, we reported that the in vivo repopulating ability of CD34 + UCB cells could be expanded in 2-week cultures containing at least FL and TPO and that the stromal support was not required. 22 The requirement for a stromal microenvironment in ex vivo amplification of the HSPC remains controversial. Endothelial-based culture of UCB CD34 +
− cells has been reported to obtain higher CAFC expansion (11-fold the input) as compared to four-fold in the stroma-free system after 3 weeks of culture in the presence of the cytokines FL, TPO, SCF, IL6 and GM-CSF. 23 A recent study by Lewis et al 24 showed that both myeloid and lymphoid progenitors from UCB and mobilized peripheral blood can be expanded in the presence of the murine fetal liver cell line AFT024 under 2 to 5 week stromacontact and stroma-non-contact culture conditions supplemented with at least FL and TPO. Although in the absence of exogenous cytokines stroma-support fails to significantly expand in vitro and in vivo repopulating cells in stroma-supported cultures, 12, [25] [26] [27] [28] the inclusion of TPO in such cultures dramatically increased the longevity of hemopoietic activity and maintenance of repopulating ability of stem cells. 29 All of these data together suggest that both stromal cells and exogenous cytokines, including at least TPO, are required for maintenance and/or expansion of HSPC in cultures exceeding a time period of about 2 weeks.
Although a shorter culture period is favorable in a clinical setting, the extent of HSPC expansion (three-to 15-fold increase of CAFC and SRA) obtained in 1 to 2 week cultures is not sufficient for a successful clinical application. 22 Therefore, in the present study we further examined whether HSPC expansion could be improved when cultured for more than 2 weeks, and whether the presence of BM-derived stromal cells, and combinations of specific cytokines affected the HSPC maintenance or expansion. As we have previously documented that certain BSA batches were inhibitory for murine HSPC expansion due to their TGF␤ 1 content, we have also compared the effect of BSA on human HSPC cultures in the present study.
Materials and methods

Human umbilical cord blood cells
Human UCB samples were collected from the umbilical cord vein after full-term delivery by the nursing staff of the Department of Obstetrics and Gynaecology at the Sint Franciscus Gasthuis (Rotterdam, The Netherlands). Informed consent for taking samples for clinical study was obtained. UCB was collected in sterile flasks containing 10 ml citrate-glucose as anticoagulant, stored at room temperature and processed within 24 h of collection.
Isolation of CD34
+ cells
Low-density cells were isolated using Ficoll-Hypaque density centrifugation (1.077 g/cm 2 , Lymphoprep; Nycomed Pharma, Oslo, Norway). After centrifugation at 600 g for 15 min, the mononuclear cell (MNC) band at the interface was removed, washed twice with Hank's balanced salt solution (HBSS; Gibco, Breda, The Netherlands) and resuspended in Iscove's modified Dulbecco's medium (IMDM; Gibco). The MNCs were stored in liquid nitrogen until use. After thawing and before the CD34 + hemopoietic progenitor cells were isolated we pooled three to 16 different UCB samples. The CD34 + cells were harvested from the mononuclear cells using VarioMacs Immunomagnetic Separation System (Miltenyi Biotec, Bergisch Gladbach, Germany). The CD34 + cells were labeled indirectly using a hapten-conjugated primary monoconal antibody and an anti-hapten antibody coupled to MACS microbeads. The magnetically labelled cells were enriched by passing them twice through a VarioMacs positive selection column to reach a final purity of Ͼ90% CD34 + cells. A nuclear cell count was performed and the progenitor and stem cell numbers in the CD34 + selected UCB cells were assayed by CFC, CAFC and NOD/SCID repopulating cell assays. In addition, the immunophenotypic characteristics of the cells were assessed and part of the CD34 + cells were cultured for 10 weeks.
Hemopoietic growth factors
The following cytokines were used: recombinant human stem cell factor (SCF) and FLT3-ligand (FL), both gifts from Amgen (Thousand Oaks, CA, USA), recombinant human interleukin 6 (IL6), recombinant human granulocyte-macrophage colonystimulating factor (GM-CSF), recombinant human granulocyte colony-stimulating factor (G-CSF) and recombinant murine stem cell factor (SCF), all gifts from Genetic Institute (Cambridge, MA, USA); recombinant human thrombopoietin (TPO, a gift from Genentech, South San Francisco, CA, USA), recombinant human erythropoietin (EPO, Boehringer, Mannheim, Germany) and recombinant human IL3 (Gist Brocades, Delft, The Netherlands).
Extended long-term expansion cultures
Various culture conditions were used in five consecutive experiments. In the first experiment 50 000 CD34
+ UCB cells were cultured in six-well tissue culture plates (Costar, Badhoevedorp, The Netherlands) in an 1 ml IMDM-cocktail containing 10% fetal calf serum (FCS; Summit, Fort Collins, CO, USA), 1% bovine serum albumin (BSA; Sigma, Zwijndrecht, The Netherlands) supplemented with penicillin (100 U/ml, Gibco), streptomycin (0.1 mg/ml, Gibco), ␤-mercapto-ethanol (10 −4 m, Merck, Darmstadt, Germany), bovine insulin (4 mg/ml, Gibco), cholesterol (15 m, Sigma), linolic acid (15 m Merck) iron-saturated human transferrin (0.62 g/l, Intergen, Uithoorn, The Netherlands), cytidine (10 −3 g/ml, Sigma), adenosine (10 −3 g/ml, Sigma), uridine (10 −3 g/ml, Sigma), guanosine (10 −3 g/ml, Sigma), 2′-deoxycytidine (10
g/ml, Sigma), 2′-deoxyadenosine (10 −3 g/ml, Sigma), thymidine (10 −3 g/ml, Sigma), 2′-deoxyguanosine (10 −3 g/ml, Sigma) and the cytokines FL (50 ng/ml), TPO (10 ng/ml), SCF (100 ng/ml), IL6 (100 ng/ml). The cells were cultured with the following combination of cytokines: FL + TPO, FL + TPO + SCF, FL + TPO + IL6, FL + TPO + SCF + IL6, or SCF + IL6. Cultures were set up using six to eight replicates of each cytokine combination. In the subsequent two studies 50 000 CD34
+ cells were cultured in tissue culture 25T-flasks (Falcon, Etten-Leur, The Netherlands) in 4 ml IMDM-cocktail containing 20% FCS with the same cytokine combinations. The effect of the murine FBMD-1 stromal layer on the in vitro repopulating ability was assessed for the same cytokine combinations. Insulin was not added in the stromal groups because it potently stimulated adipogenesis in FBMD-1 cells. Finally, in the last two studies 35 000 and 40 000 CD34 + cells were deposited on FBMD-1 stromal layer in tissue culture 25T-flasks in 4 ml IMDM-cocktail without BSA containing 20% FCS supplemented with the following cytokines: FL + TPO, FL + TPO + SCF, FL + TPO + IL6 and FL + TPO + SCF + IL6. The cytokines FL and TPO were added twice a week during the culture period.
The cultures were maintained with splitting of the cultured cells every 1 to 2 weeks starting from the second week of culture. When stroma-supported cultures had to be split, the adherent and non-adherent compartments of all corresponding dishes or flasks were pooled, and cells were reinoculated into culture on a newly formed stroma. If at splitting, a part of the cells was removed for analysis (on week 2 and 5), this was compensated for in the calculations for total support. The cells were incubated at 37°C and 10% CO 2 in a humidified atmosphere and harvested at different time points by collecting the supernate of each well or flask, whereafter all groups were trypsinized with trypsin-EDTA (Life Technologies, Breda, The Netherlands) to include all the adherent cells. The content of the various wells or flasks belonging to a single group were pooled, centrifuged at 250 g for 10 min and resuspended in IMDM. Suitable aliquots of the output suspensions were assayed in CFC, CAFC and SRC assays for determination of progenitor and stem cell numbers. The immunophenotypic characteristics of the cultured cells were also assessed. Remaining cell numbers of the output suspensions were cultured further for analysis at later time points.
Clonogenic assay
Granulocyte-macrophage colony-forming unit (CFU-GM) and burst forming unit-erythroid (BFU-E) progenitor cells were assayed using a semisolid culture medium (1.2% methylcellulose), containing IMDM supplemented with 10% FCS, ␤-mercapto-ethanol (5 × 10 −5 m), penicillin (100 U/ml), streptomycin (0.1 mg/ml), human(hu)-EPO (1 U/ml), hu-IL3 (20 ng/ml), hu-GM-CSF (5 ng/ml), hu-G-CSF (50 ng/ml) and murine-SCF (100 ng/ml). Duplicate cultures were plated in 35 mm tissue culture dishes (Falcon) and incubated at 37°C and 10% CO 2 in a humidified atmosphere for 14 days. Colonies containing 50 cells or more were scored at day 14 using an inverted light microscope.
Cobblestone area forming cell assay
Confluent stromal layers of FBMD-1 cells in flat-bottom 96-well plates (Falcon) were overlaid with UCB cells in a limiting dilution set up as described. 30 Briefly, 12 successive two-fold dilutions were used for each sample with 15 wells per dilution. The percentage of wells with at least one phase-dark hemopoietic clone (cobblestone area) of at least five cells beneath the stromal layer was determined at weeks 2 and 6. At initiation of the cultures 250 CD34
+ UCB cells per well were plated in the first dilution, while after cultures 200-1000 CD34
+ input equivalent cells per well were used in the first dilution. The CAFC frequencies were calculated using Poisson statistics.
Immunophenotypic analysis
At least 50 000 fresh or cultured CD34
+ cells or femoral bone marrow cells of the NOD/SCID mice were stained with antihuman CD45/CD33, CD34/CD38 or CD34/CD19 (fluorescein isothiocyanate (FITC)-or phycoerythrin (PE)-conjugated) labeled monoclonal antibodies (Immunotech, Mijdrecht, The Netherlands). The cultured cells were also analyzed with antihuman CD34, CD38 and CXCR4 (Becton Dickinson, Woerden, The Netherlands) using allophycocyanin (APC), FITC and PE-conjugated monoclonal antibodies, respectively. Human cells from the femoral bone marrow of the NOD/SCID mice were also stained with anti human CD15/CD33, CD20/CD19, CD3/CD4 and CD3/CD8 to analyze the multilineage differentiation. After incubation of the cells in phosphate-buffered saline (PBS; Life Technologies, Breda, The Netherlands) containing 0.5% BSA and 2% normal human serum for 30 min on ice, the cells were washed in PBS with 0.5% BSA and resuspended in 0.35 ml PBS. Just before the acquisition 7-aminoactinomycin (7-AAD; Molecular Probes, Leiden, The Netherlands) was added to each sample to determine the viability of the cells. APC, FITC and PE-conjugated mouse isotype antibodies were used as control for each group. At least 10 000 events were acquired using fluorescenceactivated cell sorting (FACS) analysis (Becton Dickinson).
NOD/SCID repopulating cell (SRC) assay
The NOD/LtSz-SCID/SCID (NOD/SCID) mice, 8 to 13 weeks of age, were used as recipients of human cell grafts. The NOD/SCID mice were bred, maintained and used under specific pathogen-free conditions in a laminar airflow unit, supplied with sterile food and acidified drinking water containing 100 mg/ml ciprofloxacine. All mice were sublethally irradiated with 3.5 Gy from a 137 Cs source (Gammacell, Atomic Energy of Canada, Ottawa, Canada) 1 to 4 h prior to intravenous transplantation. At initiation of the experiment the mice were transplanted with 100 000 CD34 + uncultured cells and at week 2 of cultures with 50 000 input equivalent cells. At week 5 of culture each mouse was infused with 391, 195, 391, 195, 195 or 195 input equivalent cells for the groups FL Leukemia + TPO, FL + TPO + SCF, FL + TPO + IL6, FL + TPO + SCF + IL6, SCF + IL6 or stroma-supported FL + TPO, respectively, and at week 10 of culture with 73, 37, 73, 37, 37 or 37 input equivalent cells for the same groups, respectively. The number of mice used for each group varied from three to four. Six weeks after transplantation mice were killed by CO 2 inhalation and bone marrow cells were harvested by flushing all cells from two isolated femurs per animal. After counting, the cells were analyzed by FACS to determine the human cell engraftment in each mouse. Between 10 000 and 100 000 events were acquired for analysis. If the percentage of CD45 + cells was Ͼ0.1% the mice were considered positive, while all mice with a percentage Ͼ5% were analyzed for expression of lineage-specific markers.
Statistical analysis
The values are reported as mean ± 1 s.d. The significance levels were determined by two-tailed Mann-Whitney test analysis.
Results
Uncultured CD34
+ UCB cells 
CXCR4
+ phenotypes, which are assumed to contain all BM repopulating ability, was 3 ± 1% (as percentage of total NC in five experiments) and 4% (as percentage of total CD34
+ cells determined in one experiment), respectively. The mean number of clonogenic cells was 29 688 ± 9781 CFU-GM and 10 500 ± 4093 BFU-E per 10 5 input cells. The CAFC week 2 and 6 frequencies as a measure of transiently and tentative long-term repopulating stem cells, respectively, ranged from 6230 to 23 566 and 3988 to 9997 per 10 5 input cells, respectively. To analyze the ability of uncultured CD34 + cells to give multilineage engraftment in the BM of NOD/SCID mice, 100 000 CD34 + UCB cells per mouse were injected i.v. into groups of sublethally irradiated mice. Six weeks after transplantation the mice were killed, BM cells harvested from both femurs and analyzed for the presence of different lineages of human hemopoietic cells using FACS. One hundred thousand CD34
+ cells were able to multilineage engraft 100% of the mice. The percentage of CD45 + cells, as a marker for the presence of human hemopoietic cells in the murine BM, ranged from 1% to 19%.
Cultured CD34
+ UCB cells
Stroma-free ELTC:
To assess the ability of serum-containing stroma-free cultures to support the growth of primitive hemopoietic progenitors including CD34 + subsets, CFC, CAFC and NOD/SCID repopulating ability (SRA), their content was determined in each sample before and during 10 week cultures in the presence or absence of cytokines. First we evaluated the influence of medium conditions for expansion of CD34 + cells. The addition of BSA gave a significant increase of the absolute number of NC, CD34
+ subsets and CFU-GM (P Ͻ 0.05). While the absence of BSA resulted in loss of early progenitors, the presence of BSA was able to give maintenance or moderate expansion of these cells during the culture period (Table 1) . For this reason, the data below represent the results obtained under BSA-containing conditions. Stroma-free culture of CD34 + UCB cells in the presence of different combinations of cytokines resulted in a dramatic expansion of NC and CD34
+ subsets (Figure 1 ). The fold-increase of the CD34 + phenotype as a measure of HSPC, and that of the CD34 + CD38 − phenotype as an indicator of quiescent and functionally primitive population of HSPC, varied from 14 to 1197 and 54 to 30 937, respectively, at week 10 of the cytokine-supplemented cultures. In general, there was a rapid increase in the fold-expansion of these parameters during the first few weeks of culture, whereafter the rate of increase became slower. Interestingly, the CD34 + CD38 − CXCR4 + cells as an estimation of the NOD/SCID marrow repopulating fraction of HSPC 31 showed a rapid increase until week 2 of stroma-free cultures, a plateau between week 2 and 5 and a very rapid decline to undetectable levels at week 10. The CFU-GM ( Figure 2 ) showed a continuous increase during the first 5 weeks of stroma-free culture whereafter their levels remained more or less constant, while the BFU-E were undetectable in all cytokine groups at all time points analyzed. Among the different in vitro parameters determined in ELTC, the CAFC subsets showed the lowest levels and fastest disappearance in all cytokine groups under stroma-free conditions except in the FL + TPO + IL6 group, where there was a continuous increase during stroma-free culture reaching almost 10-fold expansion at week 10. Interleukin 6 +/− SCF synergized with FL + TPO to promote the early and late progenitor amplification in terms of CAFC subsets and CFU-GM. The addition of SCF to the cytokine combination FL + TPO in stroma-free cultures resulted in loss of CFU-GM and CAFC subsets at week 10 of culture which was abrogated by the addition of IL6.
In order to evaluate whether the expanded cells maintained their ability for multilineage engraftment in the NOD/SCID mice we studied the SRA of the cytokine-supplemented stroma-free cultured cells. In agreement with our previous observations, a considerable expansion of the ability of CD34 + UCB cells to engraft the BM of sublethally irradiated NOD/SCID mice was observed after 2 weeks of culture ( Figure  3 ). The percentage of human chimerism was 49 ± 42, 62 ± 29, 68 ± 29, 62 ± 27, 13 ± 10 for FL + TPO, FL + TPO + SCF, FL + TPO + IL6, FL + TPO + SCF + IL6 and SCF + IL6, respectively, at week 2 of culture. The percentage of human chimerism in the BM of mice infused with cultured cells ranged between 1% and 90% with no significant difference between the cytokine combinations when at least FL + TPO was included. In all FL + TPO containing groups, higher levels of human chimerism on average were detected in mice infused with cultured cells equivalent to 50 000 input cells than in mice infused with 100 000 uncultured CD34 + UCB cells. The cultures with SCF + IL6 alone led to human chimerism levels as high as that of uncultured CD34
+ UCB cells and ranged between 1% and 20%. Addition of SCF +/− IL6 to the cytokine combination FL + TPO did not significantly affect the expansion of the SRA after 2 weeks of culture. The expression of lineage markers on human cells present in the femoral marrow of the mice at 6 weeks post-transplant showed no significant difference between the cultured and uncultured cells ( Table  2) . Although we were able to expand the ability of UCB CD34 + cells to multilineage engraft the BM of NOD/SCID mice in 2 week cultures, hardly or no detectable levels of human engraftment were observed in the mice transplanted when the CD34 + UCB cells had been cultured for 5 weeks or longer.
Stroma-supported ELTC:
To investigate whether stroma would improve the support of primitive HSPC, the CD34 + UCB cells were cultured on the murine BM-derived stromal cell line FBMD-1 using the same cytokine combinations and liquid culture conditions as used for stroma-free cultures, except for insulin. Insulin was omitted from these cultures as it induced extensive adipogenesis and consequently affected the rigidity of the stromal layers. Under suboptimal culture conditions, eg using medium lacking BSA, stroma was required to increase the absolute number of CFC, CAFC and CD34
+
CD38
− cells as compared to stroma-free culture (Table 1). The NC, CD34 + subsets and CFU-GM expansions were significantly improved with the addition of BSA into the medium both under stroma-free and stroma-supported conditions (P Ͻ 0.05), as were the CAFC week 6. We have therefore included BSA, except otherwise specified, into the medium to improve the growth of the inoculated CD34
+ cells in the remainder of the experiments. The stroma support withLeukemia out additional cytokines gave a maximum of 26-, 161-and 74-fold increase of the CFU-GM, CD34
+ and CD34 + CD38 − subsets, respectively, during the culture period of 10 weeks, however, it did not lead to an expansion of CAFC subsets (Figures 1 and 2 ). At weeks 2 and 5 of culture, no statistically significant difference in HSPC parameters was observed between stroma-free and stroma-supported cultures in the 
− and CAFC subsets with at least one-log increase as compared to the corresponding stromafree parameters at week 10 of culture, with the exception of the cytokine combination SCF + IL6 which showed similar (NC, CD34 + ) or decreased (CD34 + CD38 − , CFU-GM and CAFC subsets) levels of the HSPC parameters (Figures 1 and 2 ). More interesting was the observation that the CD34
+ cells, which have been shown to represent the BM repopulating progenitors in uncultured grafts, 31 required both stromal support and cytokines to expand for a time period of more than 5 weeks (Figure 1) . The stroma support gave a similar increase of CFU-GM as the corresponding stroma-free groups under FL + TPO containing conditions (Figure 2) . In contrast to the stroma-free cultures, stroma support induced a continuous increase of CAFC subsets during the culture period when at least FL + TPO was included, reaching a maximum of 89-fold (mean 72-fold) expansion with FL + TPO + IL6 at week 10 of culture ( Figure 2) . Additionally, the inclusion of SCF to the cytokine combination FL + TPO under stroma-supported conditions showed a trend of diminished generation of CFU-GM and CAFC subsets as compared to the FL + TPO group at week 10 of the culture (CFU-GM, 141 vs 977-fold; CAFC week 6, 10 vs 54-fold). This effect of SCF was abrogated by the addition of IL6. In conclusion, in FL + TPO containing cultures stroma support dramatically increased the expansion of HSPC as assessed by CAFC and CD34
+ cells. We pre- viously reported that FL + TPO were required and sufficient to give a comparable high SRA expansion in 2 week cultures. We therefore evaluated only the stroma-supported FL + TPO group using the NOD/SCID assay in this study (Figure 3 ). The percentage of human chimerism was 62 ± 26%, when 50 000 input equivalent cells were inoculated from FL + TPO supplemented stroma-supported 2 week culture, which was as high as under stroma-free conditions in the presence of at least FL + TPO. A similar pattern of multilineage SRA expansion as compared to stroma-free cultures was observed with an increase at 2 weeks, whereafter hardly or no detectable levels of human engraftment with FL + TPO propagated cells was observed.
Comparative expansion of various parameters after ELTC:
In the present study, the presence of HSPC in uncul- 
Cells infused into NOD/SCID mice were either uncultured, or propagated under stroma-free or stroma-supported conditions. The inocula were either 100 000 CD34 
CD38
− cells was not related to the CFC, CAFC and SRA present in the inoculum of cultured cells, both in stroma-free and stroma-supported conditions (Figure 4 ). There was also no direct correlation between the number of CFC present in the inoculum of cultured cells and repopulation of sublethally irradiated recipients or CAFC week 6. This is not surprising, as it is known that CFC define a relatively mature population of progenitors lacking long-term repopulating ability. Also the CAFC week 6, which is considered to include long-term in vitro repopulating stem cell subsets, was not indicative for the in vivo repopulating ability. The expansion of CAFC week 6 estimated in the present study was maximally 17-fold at week 2 and 89-fold at week 10 of cultures. However, the estimated SRA expansion, as calculated previously, 22 was approximately 14-fold at week 2, whereafter SRA was lost. In summary, our data show increasing incongruency with increasing culture time between the different surrogate methods used to quantitate stem and progenitor cells. Especially the flow cytometry and CFC generation greatly overestimated the in vivo repopulating ability and CAFC content of these cells at the time points analyzed.
The expression of CD38 antigen after ELTC:
The incongruency of the dramatic expansion of CD34 + 38 − cells and the limited increase in SRA and CAFC numbers during ex vivo propagation made us question whether the generated CD34 +
CD38
− cells arose from the input CD34 + CD38 − cells or by loss of CD38 antigen expression on more lineage-restricted cell populations. Therefore, we assessed immunophenotypically the expression of lineage markers within the CD34 +
− cell population during the 10 week culture period and determined the corresponding progenitor content of UCB CD34
+ cells under BSA-lacking stroma-supported conditions in the presence of at least FL + TPO. The UCB CD34 + cells maintained in vitro their ability to differentiate into myeloid cells (CD33 + ), monocytes (CD14 + ) and granulocytes (CD15 + ) for 10 weeks (Table 3 ). The CD34 + cells co-expressing CD2 (T-lymphocytes, natural killer cells), CD19 (B-
Figure 4
Comparative expansion of in vitro and in vivo HSPC parameters during 10 weeks stroma-free and stroma-supported culture of CD34 + UCB cells. Data represent the mean of two independent experiments for CD34 +
CD38
− and CAFC week 6 and the mean of four mice at each time point analyzed within one experiment for estimated SRA. The calculation of SRA expansion has been performed as previously published.
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Table 3
Lineage restriction within CD34 + subset before and after stroma-supported culture of CD34 + UCB cells 
Culture conditions Lineage restricted cells as % of CD34
+ subset CD2 + CD19 + CD33 + CD14 + CD15 + CD41 + CD71 + GlyA + Uncultured 1 ± 1 1± 1 9 4± 5 N 3± 0 5± 3 1 2 a N 2-week cultured FL + TPO 9 ± 9 1± 1 9 2± 1 N 1 3± 0 3± 2 4± 0 N FL + TPO + SCF 6 ± 6 N 9 2± 1 1± 1 9± 2 2± 1 3± 0 N FL + TPO + IL6 10 ± 10 N 94 ± 0 4± 2 1 5± 0 N 4± 1 N FL + TPO + SCF + IL6 8 ± 8 N 9 5± 0 3± 2 1 7± 4 N 3± 1 N 5-week cultured FL + TPO N N 81 ± 19 N 2 ± 1 N 1± 1 N FL + TPO + SCF N N 74 ± 25 1 ± 1 5± 1 N N N FL + TPO + IL6 N N 74 ± 26 1 ± 1 1 1± 6 N N N FL + TPO + SCF + IL6 N N 78 ± 22 4 ± 4 9± 2 N N N 10-week cultured FL + TPO N N 83 ± 16 2 ± 1 4± 1 N 1± 1 N FL + TPO + SCF N N 60 ± 10 N 4 ± 2 N N N FL + TPO + IL6 N N 43 ± 1 1± 1 3± 0 N N N FL + TPO + SCF + IL6 N N 76 ± 23 2 ± 2 6± 3 N1±
CD38
− cells expressing CD33 antigen ranged between 15 and 27%, 2 and 40% and 17 and 72%, respectively (Table  4) . No significant difference in expression of the detected markers was observed between the different cytokine combinations used. These observations clearly indicate that many CD34 +
− cells were in fact lineage marker expressing cells that failed to express the CD38 epitope.
Discussion
In the present study, we have evaluated the ability of a murine BM-derived stromal cell line to increase maintenance and/or undifferentiated expansion of UCB CD34
+ cells in extended cultures. We show that both stromal support and the inclusion of BSA dramatically improved the expansion of CAFC subsets in cultures exceeding a time period of 2 weeks and that important differences exist between the used stem and progenitor cell assays. Especially, the enumeration of CD34 + subsets and CFC generation greatly overestimated the expansion of CAFC or SRA at the time points analyzed, confirming that the different surrogate methods to quantitate HSPC are unlikely to detect identical populations after culture.
There are extensive data on the supportive capacity of stromal cells on the maintenance of primitive stem cells and their ability to generate progenitor cells in long-term cultures. 32 The plethora of cytokines that have become available in the last decennium has offered an attractive alternative for the use of stroma in ex vivo expansion of stem cells for clinical appli- ) if they additionally expressed at least one of the following markers CD2, CD14, CD15, CD19, CD33, CD41, CD71 or GlyA. If any of these markers was detected on less than 0.1% of the cells at any time point in any one group, these data were excluded from this Table. cations. However, the combination of stroma support and cytokines has been insufficiently explored, but potentially may lead to dramatic improvement of the longevity of repopulating characteristics of HSPC as is the case when TPO is induced in stroma-supported BM cultures. 29 In the absence of exogenous cytokines, proliferation of HSPC in the presence of BMderived stroma is associated with loss of most of the in vivo repopulating ability of hemopoietic progenitors. 25, 33, 34 Brandt et al 28 showed that 3 weeks stroma-free culture of CD34 + Thy-1 + human BM cells with lineage-negative markers resulted in impairment of engraftment ability in NOD/SCID mice, which could be overcome by coculture with a layer of porcine microvascular endothelial cells. We and others have previously reported that stroma-conditioned medium enhanced the expansion of primitive HSPC from CD34 + -selected mobilized peripheral blood in short-term cultures, while stromasupport was also required for optimal maintenance and graft quality. 12, 35, 36 In addition, Xu et al 37 have shown that CD34 +
CD38
− UCB cells could maintain their in vivo repopulating ability during a 4-week culture period, when supported by an embryonic stromal cell line derived from the murine aorta-gonad-mesonephros region, a location currently considered to generate the first definitive HSPC. There are still insufficient data on which factors contribute to maintenance and/or expansion under stromal conditions. O-sulphated GAGs have been shown to aid the long-term maintenance of LTC-IC under stroma noncontact conditions, 38 while LIF have been suggested to be responsible for maintaining and expanding transplantable CD34
+
Thy1
+ cells in stroma-supported cultures through an action on the stroma. 39 It is likely, that additionally cell adhesion molecules and extracellular matrix molecules contribute to the specific contextual interaction between stem cells and the stromal environment, and that chemotactic factors such as SDF-1 and specific lipids help to guide and maintain HSPC in their niches. [40] [41] [42] [43] [44] The present study indicates that stroma and cytokines are required to obtain expansion of CAFC when cultured for more than 2 Leukemia weeks. Also the CD34
+ cells representing the NOD/SCID repopulating cells 31 required both stromal support and cytokines to expand over a time period of 5 weeks. Our data contrast with the previous data published by Piacibello and colleagues indicating no stromal requirement in expansion of LTC-IC for more than 6 months and of SRC for 10 weeks. In initial studies these authors used FCS in stroma-free long-term cultures for evaluation of optimal conditions which resulted in massive and prolonged expansion of in vitro hemopoietic progenitors (CFC) and more primitive hemopoietic stem cells (LTC-IC) from UCB CD34 + cells. 19, 20 Secondly, they switched to pooled human serum as a substitute for FCS in order to make a step further toward a clinical application and assessed whether the combination of early acting cytokines with best results could maintain and amplify SRC. 21 The latter resulted in an increase of more than 70-fold the input SRC after a culture period of 9 to 10 weeks. Therefore, the differences observed between these and our extended long-term data may be partly attributable to the culture conditions used with special reference to serum batches or the source of serum used. Also the sources of cytokines and the cell purification procedures may have contributed to the contradictory results.
Previous attempts to expand stem cells in vitro have also emphasized the role of the early acting cytokines FL, TPO, SCF and IL6 in regulation of HSPC growth and survival. [8] [9] [10] [11] [45] [46] [47] Using combinations of these cytokines, we observed synergistic effects in support of early progenitors for extended periods of 10 weeks if at least FL + TPO were included. While we observed that the use of cytokines alone expanded early progenitors, and the use of stroma alone decreased their numbers, the combination of stroma and cytokines greatly increased the maintenance and production of HSPC in our ELTC. The effect of cytokines could be partly explained by a direct effect on HSPC, however, they are also likely to act indirectly by an effect on stroma. Human FL, TPO and IL6 are known to exhibit cross-species activity on mouse cells. Unpublished observations in our laboratory indicate that the FBMD-1 cell line does not express murine c-kit (receptor for SCF) and FLT3 (receptor for FL), however, it does express the murine IL6-receptor-␣ and c-mpl (TPO receptor), while human TPO down-modulates IL6-receptor-␣ expression on these cells. These data substantiate our contention that at least the cytokines TPO and IL6 used in the present study might have reacted on both HSPC and stroma.
Interestingly, in SCF + IL6 stimulated cultures, stroma decreased the expansion magnitude of CD34 + and CD34
+
CD38
− cells, CFU-GM and CAFC subsets as compared to the stroma-free conditions. A possible explanation for this observation is that the exogenous soluble ligand SCF may compete with the stroma membrane-bound SCF for c-kit receptors on HSPC, assuming that the interaction with the membrane-bound SCF results in the modification of the most effective signaling pathways in maintaining HSPC. The importance of membrane-bound SCF in hemopoiesis, fertility and skin pigmentation has been documented in studies on the anemic mouse traits W/W v and Sl/Sl d . 48, 49 An alternative explanation for this SCF effect on primitiveness of HSPC observed in the presence of stroma is that SCF induces differential expression of adhesion molecules on HSPC and/or stromal cells, which in turn could cause different stem cell subsets to contact different adherent cell compartments capable of differently affecting the HSPC self-renewal.
In agreement with our previous observation, 22 human cells were found in the BM of NOD/SCID mice following transplantation with 2-week cultured cells. These cells showed multilineage engraftment in vivo, and no significant difference between the cytokine combinations used was observed if at least FL + TPO was included. The extended cultivation time and consequent dilution of input equivalent stem cells over time prohibited the use of a limiting dilution set-up for calculating the numbers of SRC present in our samples. Instead, we have used the remaining cells to infuse limited numbers of NOD/SCID recipients to arrive at meaningful repopulation percentages. For this reason, we were not able to precisely determine the fold expansion of SRC, but rather calculated an estimated increase in the ability of the infused cells to repopulate the BM of the recipient mice with human hemopoietic cells as previoulsy published. 22 The very high percentages of human cells (over 90%) in some groups having received cultivated cells indicates that we might have reached the maximal human chimerism percentage in the NOD/SCID assay, which in turn suggests that our SRA calculations are conservative. While at week 2 the expansion of SRA was similar under both stroma-free and stroma-supported conditions, after 5 weeks of culture cells were hardly (FL + TPO + IL6 group), or not at all able to give detectable levels of human engraftment in the mice. Possibly, this low SRA is due to a loss of NOD/SCID repopulating cells (SRC), or due to their differentiation. It is not yet clear whether inclusion of FCS has an inhibitory or beneficial effect on the maintenance or expansion of SRC. 50, 51 However, using 10% or 20% FCS, we recently obtained expansion of in vivo repopulating ability of UCB CD34
+ cells (Ref. 22 , and present study). It is very likely that the concentration or batch of FCS used may be responsible for different results. Alternatively, SRC in the current study may have been diluted out as limited numbers of input equivalent cells were infused at weeks 5 and 10 of the culture with 37 to 391 input equivalent cells infused per mouse, when compared with the 2-week time point where we transplanted 50 000 input equivalent cells per mouse. As a fourth alternative, it could be that more than 2-week cultured cells show a decreased ability to home to and to expand in the BM of NOD/SCID mice. A study by Peled et al showed that the chemokine stromal cell derived factor (SDF)-1 and its receptor CXCR4, which is expressed on some CD34
+ CD38 − cells amongst others, may be important for engraftment of sublethally irradiated NOD/SCID mice, although there is evidence that CXCR4 is heterogeneously expressed on SRC. 31, 52 The cytokines SCF and IL6 induced CXCR4 up-regulation on CD34
+ cells, which subsequently potentiated migration of these precursor cells and their engraftment in primary and secondary transplanted mice. Thus, the use of at least SCF +/− IL6 in the present study might have caused increased homing potential of the CD34 + UCB cells in 2-week cultures, which in turn contributed to the increased SRA.
It is generally accepted that the CD34 + CD38 − phenotype in uncultured material defines an immature population of progenitors and includes many CAFC week 6/LTC-IC and all long-term in vivo repopulating cells. However, in the present study the expansion of CD34 + CD38 − (CXCR4 + ) cells was not related to the CAFC and SRA after culture. These results are in agreement with previously published data indicating a differential maintenance of LTC-IC and SRC during stromal or endothelial-based cultures in 3-week cultures of UCB or BM cells. 23, 34 Recently, others have also reported a large expansion of CD34 +
− cells (166-fold) during retroviral transduction period of 2 to 6 days without an increase in SRC numbers indicating a dissociation between the primitive CD34 +
− phenotype and SRC function. 51 Overall, our data indicate that the different surrogate methods to quantitate HSPC show great incongruency with increasing culture time, in which especially phenotypic characterization and the CFC assay seem to greatly overestimate the in vivo and in vitro repopulating ability of cultured cells at the time points analyzed. One of the essential issues that we wished to clarify was whether the dramatic CD34 +
− expansion during culture arose from the input CD34
+
CD38
− cells or by downregulation of CD38 antigen expression within a population of cultured CD34 +
+ cells that no longer contained any long-term repopulating ability, both in vitro and in vivo. While preparing this manuscript, Von Lear et al 53 demonstrated for the first time that during 4 days of stroma-free culture the CD34 +
+ cells lost the CD38 antigen while remaining CD34 + resulting in an overestimation of the expansion of the CD34 +
− population. In our study we evaluated immunophenotypically the expression of lineage-restricted markers within the CD34 + CD38 − cell population under BSA-lacking stroma-supported conditions during 10 weeks of culture. Remarkably, although before culture the CD34 +
− cells were all Lin − , after culture the majority of the CD34 + CD38 − (Ͼ70%) cells co-expressed lineage restricted markers. These observations clearly indicate that this phenotype is not a reliable indicator for HSPC assessment after culture.
